Optimizing peptide epitope-based autoantibody detection in cancer patients

Area of Science:

• Immunology
• Oncology
• Biomarker Discovery

Background:

• Autoantibody (autoAb) responses are crucial in endogenous anti-tumor immunity.
• AutoAbs are gaining attention as cancer biomarkers, especially with immune checkpoint inhibitor therapy success.
• Measuring autoAbs against B-cell epitopes offers an alternative to purifying recombinant proteins.

Purpose of the Study:

• To optimize peptide-based autoAb measurement for increased sensitivity in cancer patients.
• To evaluate a novel approach using mixed peptides conjugated on microspheres versus a single dominant peptide epitope.
• To compare autoAb detection using mixed B-cell epitopes versus single epitopes in Luminex multiplex assays.

Main Methods:

• Development of a Luminex microbead-based multiplex assay.
• Conjugation of mixed peptide B-cell epitopes onto microspheres.
• Comparison of mixed peptide conjugates with single dominant peptide conjugates using cancer/germline antigens (NY-ESO-1, XAGE-1b) and a cancer/stem cell antigen (SOX2).

Main Results:

• Using mixed peptide epitopes on microspheres significantly improved the sensitivity of detecting autoAb responses.
• The mixed peptide approach enabled the detection of autoAb responses in a larger proportion of cancer patients.
• This method is effective when full-length proteins are unavailable for microsphere conjugation.

Conclusions:

• A mixture of B-cell epitopes conjugated on microspheres is a superior method for detecting autoAb responses via Luminex multiplex assays.
• This optimized approach enhances sensitivity and patient coverage for autoAb biomarker detection in cancer.
• The mixed peptide strategy provides a valuable alternative for autoAb measurement when recombinant proteins are not feasible.